Update on taxanes in the first-line treatment of advanced non-small-cell lung cancer

Por Socinski, M.A.
Publicado em 2014

Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine–cisplatin plus necitumumab versus...

Por Paz-Ares, L., Socinski, M. A., Shahidi, J., Hozak, R. R., Soldatenkova, V., Kurek, R., Varella-Garcia, M., Thatcher, N., Hirsch, F. R.
Publicado no Ann Oncol (2016)

Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer

Por Novello, S, Scagliotti, G V, Rosell, R, Socinski, M A, Brahmer, J, Atkins, J, Pallares, C, Burgess, R, Tye, L, Selaru, P, Wang, E, Chao, R, Govindan, R
Publicado em 2009

Reply: Ongoing under-reporting of clinically relevant safety data in phase II studies of tyrosine kinase inhibitors

Por Novello, S, Scagliotti, G V, Rosell, R, Socinski, M A, Brahmer, J, Atkins, J, Pallares, C, Burgess, R, Tye, L, Selaru, P, Wang, E, Chao, R, Govindan, R
Publicado em 2010